- For Patients
- Introduction to the Marshall Protocol
- Length of the MP
- Immunopathology
- Managing immunopathology
- Food and drink
- Light restriction
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Starting the Marshall Protocol
- Resources for patients
- Marshall Protocol summary
- Palliative vs. curative treatments
- Patient interviews on Bacteriality
- Non-MP treatments
- Glossary
- The Protocol
- Marshall Protocol summary
- Publications and presentations
- Science behind immunopathology
- Science behind olmesartan (Benicar)
- Safety of olmesartan
- Resources for physicians
- Vitamin D metabolite calculator - get feedback on vitamin D results
- Therapeutic probe - best method for determining MP suitability
- Physicians' concerns about the MP
- Notice for emergency medical personnel
- The Pathogenesis
- Publications and presentations
- Science behind Marshall Pathogenesis
- Microbes in the human body
- Successive infection and variability in disease
- Autoimmune theory of disease
- Science behind vitamin D
- Metabolism of vitamin D and the VDR
- Th1 Spectrum Disorder - how chronic inflammatory diseases are related
- Transmission of bacteria and onset of chronic disease
- Evolutionary perspective on disease
- Incidence and prevalence of disease
- Evidence that chronic disease is caused by pathogens
- Diseases
- Foundation
- Related Sites
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
| home:diseases:hlh [07.26.2010] – inge | home:diseases:hlh [07.26.2010] – inge | ||
|---|---|---|---|
| Line 14: | Line 14: | ||
| * The immune system is activated. High levels of serum TNF-α, interleukins, | * The immune system is activated. High levels of serum TNF-α, interleukins, | ||
| - | * HLH has been associated with Epstein-Barr virus infection (({{pubmed> | + | * HLH has been associated with Epstein-Barr virus infection, (({{pubmed> |
| - | * Treatment of infections can reduce hemophagocytosis (hisano) | + | * Treatment of infections can reduce hemophagocytosis (({{pubmed> |
| ==== Possible mechanism for hemophagocytosis ==== | ==== Possible mechanism for hemophagocytosis ==== | ||
home/diseases/hlh.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.